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Abstract
Dystrophinopathies are X-linked diseases, including Duchenne muscular dystrophy and Becker muscular dystrophy, due to
DMD gene variants. In recent years, the application of new genetic technologies and the availability of new personalised
drugs have influenced diagnostic genetic testing for dystrophinopathies. Therefore, these European best practice guidelines
for genetic testing in dystrophinopathies have been produced to update previous guidelines published in 2010.
These guidelines summarise current recommended technologies and methodologies for analysis of the DMD gene,
including testing for deletions and duplications of one or more exons, small variant detection and RNA analysis. Genetic
testing strategies for diagnosis, carrier testing and prenatal diagnosis (including non-invasive prenatal diagnosis) are then
outlined. Guidelines for sequence variant annotation and interpretation are provided, followed by recommendations for
reporting results of all categories of testing. Finally, atypical findings (such as non-contiguous deletions and dual DMD
variants), implications for personalised medicine and clinical trials and incidental findings (identification of DMD gene
variants in patients where a clinical diagnosis of dystrophinopathy has not been considered or suspected) are discussed.
Introduction
Dystrophinopathies are X-linked genetic diseases due to
dystrophin (DMD, OMIM *300377, HGNC ID: 2928) gene
variants. The main phenotypes associated with pathogenic
DMD variants are severe Duchenne muscular dystrophy
(DMD, OMIM #310200), milder Becker muscular dystro-
phy (BMD, OMIM #300376) and isolated cardiac invol-
vement leading to the X-linked dilated cardiomyopathy
(XLDC, OMIM #302045). Rare phenotypes, such as
quadriceps myopathy or isolated high serum creatine kinase
(CK) levels (‘hyperCKaemia’), have also been described
[1–3].
In all dystrophinopathy phenotypes, males have a hemi-
zygous (or rarely mosaic) pathogenic DMD variant. Hetero-
zygous females can be asymptomatic carriers, although in
some cases they present symptoms ranging from adult-onset
mild muscle weakness and/or dilated cardiomyopathy to rare
instances of a DMD- or BMD-like phenotype [4]. The rate of
occurrence of new pathogenic variants in the DMD gene is
high, and a significant proportion of cases arise de novo; there
is also a relatively high frequency of germline mosaicism [5].
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DMD is the largest human gene in terms of genomic
length, spanning 2.2 Mb. It is an ancient gene with some
regions very well conserved across species [6], and the
oldest region at the 3′ end with homology to the Sea urchin
DMD short gene. In humans, it comprises 79 constitutive
exons encoding the muscle isoform (Dp427m), plus 6 other
alternative first exons corresponding to the two full-length
isoforms mainly expressed in brain cortex (Dp427c) and
cardiac Purkinje cells (Dp427p) and to the four shorter 3′
isoforms that are expressed in the retina (Dp260), brain
(Dp140), peripheral nerve (Dp116) and general or ubiqui-
tous (Dp71). All variant types may occur in the DMD gene:
large deletions (68%), large duplications (10%), small var-
iants (i.e. missense, nonsense, insertion, deletion, indel and
splicing variants) (22%) and atypical variants including
deep intronic variants and complex intragenic rearrange-
ments (<1%) (Table 1).
Genetic testing for dystrophinopathies is recommended
as part of routine clinical practice since a genetic diagnosis
allows: confirmation of a clinical diagnosis ensuring
appropriate care and follow up; access to personalised
treatments; carrier identification and family planning.
Where possible, genetic testing should be undertaken in
laboratories accredited for clinical diagnostic testing to an
appropriate standard, such as ISO15189.
Previous guidelines on molecular diagnostics in DMD/
BMD were published in 2010 [7]. Both the application of
new technologies (particularly next generation sequencing)
in diagnostics and the availability of new personalised drugs
have led to consensus that new and updated guidelines are
required. The guidelines presented here constitute a revision
of the previous guidelines, coordinated by authors of the
2010 guidelines and the European Molecular Genetics
Quality Network (EMQN).
The recent approval and establishment of European
Reference Networks (ERNs) across European countries has
primed large collaborative initiatives devoted to Rare Dis-
ease (RD) care and cure across European Union member
states. ERN establishment also stresses the concept of
excellence-in-health for RD care, ensuring that trained and
skilled centres maximise diagnostic success, appropriate
care and follow up for RDs. Among ERNs, the EURO-
NMD ERN [8] is dedicated to neuromuscular diseases,
including dystrophinopathies, and its mission is also to
prime revision of guidelines and to promote care equality
across countries, greatly reducing the patient burden due to
delay or absence of genetic diagnosis.
Based on previously published experiences and given the
deep psychological and socio-economic implications, the
issue of newborn screening is not included in these guide-
lines. We believe that a dedicated forum would be required
for this topic to be fully discussed and developed.
Methods
The original guidelines were based on a meeting of
29 senior scientists from Europe, the USA, India and
Australia, held in Naarden, The Netherlands in November
2008 to establish consensus best practice guidelines for
molecular diagnosis of Duchenne and Becker muscular
dystrophy [7].
An update of the guidelines was deemed necessary due
to the rapidly evolving scientific nature of genetic testing
since 2008. To achieve a broad expert consensus, a drafting
group of European-based experts, including authors from
the original guidelines, compiled evidence to support
updated recommendations for genetic testing and reporting
of dystrophinopathies culminating in the first draft version
of the guidelines in March 2019. The guidelines were then
disseminated to a global network of molecular geneticists
and clinicians from a list of 135 laboratories who currently
participate or have historically participated in the EMQN-
organised scheme for DMD between 3rd April 2019 and 1st
May 2019 for consultation and amendments. The guidelines
were also distributed to known UK diagnostic labs involved
in DMD testing for comments. The feedback was collected
and appraised by the expert drafting group and the draft
document was amended accordingly. The draft document
was then reviewed by The EMQN Management Group who
made suggestions for clarity and content improvements that
Table 1 Spectrum of DMD pathogenic variants.
Phenotype Dystrophinopathy (all) DMD BMD
Deletion (≥1 exon) 68% 61–66% 80–81%
Duplication
(≥1 exon)
10% 11–13% 6–9%
Complex
rearrangements
<0.5% <0.5% <0.5%
Total CNV 78% 74–77% 87–89%
Nonsense 9% 12–13% 3%
Frameshift 7% 6–8% 2%
Missense 0.40% 0.3–0.9% 0.5–0.7%
Splicing (≤10 bp
from intron)
5% 4–5% 5–7%
Splicing (mid/deep
intronic)a
0.6%a
Total small variants 22% 23–26% 11–13%
Distribution of DMD pathogenic variants in European families with
dystrophinopathy [49, 95]. These figures are approximate and may
differ slightly in other populations.
aDeep and mid intronic splicing variants have been estimated to
account for 0.2–1% of pathogenic variants in the DMD gene [61]; this
is the only class of pathogenic variant that is not expected to be
detected by combined Copy Number Variation (CNV) analysis and
routine sequencing of the DMD gene.
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were appraised by the expert drafting team. In October 2019
the document was amended in order to formulate the final
version of the guidelines.
Results
Variant detection—technical aspects
Deletions and duplications detection (Level 1 testing)
Since whole-exon deletions or duplications are the pre-
dominant type of pathogenic variant in the DMD gene
(~78%; Table 1), an initial screen which detects the majority
of these copy number variations (CNVs) should be the first
diagnostic test offered (refer to Genetic testing strategy
section and Fig. 1). The detection of exon CNVs is based on
quantitative methods that allow determination of the relative
copy number of all exons within the DMD gene.
Among the many quantitative methods available, multi-
plex ligation-dependent probe amplification (MLPA), is
currently the most widely applied as an initial diagnostic
test in laboratories due to the convenience, high sensitivity
[9], reduced cost and commercial availability of an assay
that is CE-marked for in vitro diagnostic use (MRC Holland
SALSA MLPA Probemixes P034 and P035). MLPA only
determines the extent of deletions or duplications to the
exon level of resolution. The kits are designed to contain
only a single probe for each of the 79 exons of Dp427m
plus exon 1 of the Dp427c isoform. Hence the reliability of
MLPA results is high for CNVs involving multiple adjacent
probes/exons, but less so if an apparent single-exon deletion
or duplication is identified. Therefore, the result must be
confirmed using an independent method (quantitative, such
as real-time PCR, or qualitative, such as Sanger sequencing,
for example) if MLPA identifies an apparent single-exon
deletion or duplication. Multiplex PCR or microsatellite
marker analysis are possible methods to confirm single-
exon deletions in males (by non-amplification of a PCR
product or microsatellite marker alongside appropriate
internal amplification controls). An independent method
will determine whether the initial result could have been
caused by a sequence variant (e.g. pathogenic or non-
pathogenic) inducing an allele dropout by preventing
hybridisation of a MLPA probe [10], or for duplications, if
the result was an anomaly. Repeating the MLPA assay may
also be appropriate for single-exon duplications. Although
rare, false-negative signals will be obtained if the probe
does not map in the mutated region (i.e. partial exonic
deletion) [11].
Among other quantitative full-gene approaches, the
oligonucleotide-based array comparative genomic hybridi-
zation (CGH) technique has proved to be very efficient in
detecting CNVs in the DMD gene [12, 13]. High-resolution
array CGH uses thousands of oligonucleotide probes to
interrogate copy number across the entire 2.2 Mb genomic
region of the DMD gene including all exons and introns as
well as 5′ and 3′ flanking regions, and thereby maps rear-
rangement intronic breakpoints to relatively narrow inter-
vals depending on the spacing of the probes at the
breakpoints. Gene-targeted high-density array CGH has a
further advantage over most other methods which generate
only a single result per exon, since most deletions or
duplications are likely to be detected simultaneously by
several oligonucleotide probes on the array. This eliminates
the possibility of a false positive result due to the presence
of a single nucleotide polymorphism (SNP) in a single
probe or primer binding site. It also can detect loss or gain
of sequences at intronic breakpoints associated with some
inversions and complex rearrangements, thereby offering a
slightly higher detection rate than MLPA [14, 15].
For both MLPA and array CGH, the information on
CNVs gives no insight on the orientation or location of
insertions, duplications or rearrangements. Also, these
techniques are unable to detect balanced rearrangements.
Both techniques can however identify non-contiguous
exon deletions or duplications which should be further
tested (see Atypical findings below).
Quantitative assays of all DMD exons have gradually
superseded techniques that interrogate only selected exons
as they offer a higher detection rate for CNVs in the DMD
gene. In particular, they allow the detection of non-
contiguous exon deletions, duplications or triplications
that occur in this huge gene, whose identification is crucial
to provide an accurate diagnosis and genetic counselling
[15, 16]. In addition, these techniques can be used for
female carrier testing. In this context, the conventional
Multiplex PCR assay initially developed to detect the
majority of DMD deletions in male patients by screening a
subset of 18 exons [17, 18] is now hardly ever used as it
does not characterise the end points of all deletions, does
not detect other CNVs, and cannot be applied to carrier
testing. Therefore, it is recommended that conventional
Multiplex PCR no longer be used for diagnostic testing and
should be replaced by a quantitative assay for all
DMD exons.
Next generation sequencing (NGS) approaches are now
routinely adopted to accurately detect single nucleotide
variants (SNVs) (see below) and have emerged as a tech-
nology with the capability to detect accurately both SNVs
and CNVs in a single assay [19, 20]. However, CNV ana-
lysis via NGS is not yet routinely adopted in diagnostics.
CNV calls from NGS data depend on high depth and uni-
formity of coverage across all target sites, and currently
available bioinformatics tools are still not sensitive enough
to reliably pick up all types of CNVs without expert
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bioinformatics knowledge and extensive validation [21, 22].
Hence, accurate and robust CNV calling is particularly
difficult for female carrier testing and for duplications in
males. Therefore, further technical and bioinformatics
improvements are still needed, but NGS-based CNV
detection will increasingly be adopted into routine
Fig. 1 Flowchart of the
recommended molecular
diagnostic algorithm for
dystrophinopathy.
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diagnostics over the next few years. Noteworthy, both short
read and long read whole-genome sequencing are beginning
to be implemented by diagnostic laboratories and may
prove to be the preferred methods for sensitive and specific
detection of both CNVs and SNVs.
When interpreting the deletion or duplication result (see
below), if the predicted severity is discrepant with the
observed clinical phenotype, it may be useful to repeat the
tests on a second sample and/or to carry out additional
laboratory tests using different methods, or offering more
detail, in order to look for an explanation for the dis-
crepancy. This additional work is not essential for genetic
diagnostic purposes and may not be possible in all centres.
However, an accurate determination of the extent of a
deletion or a duplication and of its potential impact on
transcripts may be required for the inclusion of a patient in a
genotype-based therapy.
Small variants detection (Level 2 testing)
The term ‘small variants’ is used here to collectively
describe missense, nonsense, small insertion and deletion,
indel and splicing variants. As pathogenic small variants in
the DMD gene are mostly private and are distributed all
along the gene, all 79 exons and flanking intronic
sequences should be analysed. This is usually performed by
DNA sequencing, but sequencing of RT-PCR derived
cDNA can also be carried out. Until recently, the Sanger
method (first-generation sequencing) was the most popular
and routine technique used to individually sequence all
DMD exons [23]. Sanger sequencing is highly accurate but
of course highly time consuming, therefore the new NGS
approaches have led to a rapid change in sequencing stra-
tegies. In comparison with Sanger sequencing, which can
only be performed on one target of a few hundred
nucleotides (typically one exon) per reaction, NGS enables
a large number of targets to be sequenced in parallel with
deep sequence coverage in multiple patients at one time.
While whole-DMD gene sequencing including all exons,
introns and promoter has been reported [24], current
approaches are mostly amplicon-based targeted NGS to
sequence all 79 exons and intronic flanking sequences of
the DMD gene [19, 20]. Whole-exome sequencing and
whole-genome sequencing, with targeted analysis of the
DMD gene, are also increasingly being adopted [25, 26].
Data analyses are performed using in-house pipelines or
commercially available software. Thus, NGS offers
numerous technical advantages (improved cost-effective-
ness, scalability, resolution) and can enhance the detection
of low-level somatic mosaicism in patients or probands’
mothers as compared to Sanger sequencing. High quality
sequence read depth must be sufficient across the region
analysed, and laboratories may need to carry out Sanger
sequencing of any regions falling below their validated
minimum read depth.
However, while NGS has become more widely used to
screen for unknown variants, Sanger sequencing remains
the standard method used for known familial variant testing,
validation of variants identified by NGS and prenatal
diagnosis.
RNA analysis (Level 3 testing)
In patients with an ascertained clinical diagnosis of dys-
trophinopathy but no CNVs or small variants identified,
RNA-based methods offer a valuable tool with a high
likelihood of being able to detect variants that escape
detection using level 1 and 2 DNA approaches, such as
complex rearrangements or deep intronic variants leading to
pseudo-exon insertion or cryptic splice site recognition in
the mature transcripts. These variants appear to be of low
frequency (Table 1) [27]. Conventional Sanger sequencing
can be performed on RT-PCR derived cDNA from muscle
RNA. Alternatively, a microfluidic card tool based on a
TaqMan assay can be used to profile the entire DMD
mRNA including all exon–exon junctions, and it is able to
identify multiple splicing anomalies [28]. Although patho-
genic variants have been identified in DMD mRNA from
blood [29, 30], only low level illegitimate DMD transcrip-
tion occurs in lymphocytes, so analysis is technically
challenging and any aberrant splicing may not reflect spli-
cing in muscle. Recently, alternative sources of DMD
transcripts have emerged such as stem cells [31] or extra-
cellular RNA [32] from urine that could help overcome the
difficulty of obtaining muscle biopsies in some patients.
If a pathogenic variant is identified in cDNA, it should be
followed by sequencing of the appropriate region(s) in
genomic DNA to confirm the result and allow future
genomic-based testing in relatives. Similarly, when an
intronic region corresponding to a pseudo-exon or the use of
a new intronic splice site is found in RT-PCR derived
cDNA, the genomic region surrounding the inserted
sequence should be sequenced to identify the causative
intronic variant. In some rare occasions, it may not be
straightforward or even possible to characterise the
sequence change at the genomic level responsible for the
detected structural change in the transcript.
In the near future, targeted RNA-seq approaches, whole-
transcriptome sequencing and/or whole-genome sequencing
are likely to be used to explore unsolved dystrophinopathy
cases to identify variants causing aberrant transcripts.
RNA analysis is also useful to accurately define the
splicing outcomes of DNA variants, to establish whether
genomic duplications are in direct tandem orientation,
together with their consequences on the mRNA, or to fur-
ther explore genotype-phenotype discrepancies. Altered
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splicing events (e.g. exon skipping, partial intron retention,
pseudo-exon insertions) may occur that change the pre-
dicted impact on the reading frame of genomic rearrange-
ments or exonic variants (e.g. exon skipping-associated
nonsense variants).
Genetic testing strategy
Diagnostic testing in male patients
Affected males suspected of having a dystrophinopathy are
referred for genetic confirmation of the clinical diagnosis.
Typically, dystrophinopathy is suspected on the basis of
clinical symptoms and high serum creatine kinase (CK)
levels. In some cases, family history may also be suggestive
of a dystrophinopathy. Molecular testing is usually now
requested prior to a muscle biopsy, given the high fre-
quency of deletions/duplications of one or more exons and
new high-throughput NGS methods for DMD gene
sequencing, but in some centres or in some cases a muscle
biopsy may still be needed before any genetic testing is
carried out.
Genetic confirmation of a dystrophinopathy is achieved
by demonstrating the presence of a clearly pathogenic
variant in the DMD gene. A flowchart of the recommended
molecular diagnostic algorithm is shown in Fig. 1. Since
whole-exon deletions or duplications account for ~78% of
pathogenic variants (Table 1), testing all exons of the DMD
gene for whole-exon deletions and duplications is the first
genetic diagnostic test recommended. If this analysis does
not identify a pathogenic deletion or duplication and if
dystrophinopathy is strongly suspected, then sequencing of
the entire coding region of the DMD gene is recommended.
It is not expected that DMD sequencing is available in
every laboratory, but laboratories in which it is not avail-
able should seek an arrangement with another laboratory to
carry out this analysis. If a pathogenic variant is still not
identified, then a muscle biopsy and dystrophin analysis by
immunohistochemistry (and western blot where possible)
will be needed to establish a precise clinical diagnosis. In
these cases, further molecular genetic analysis by muscle
cDNA sequencing can be undertaken by specialist centres
and will usually identify a pathogenic variant. Therefore,
>99% of genetic diagnosis of dystrophinopathy is achiev-
able using the entire cohort of testing (1st, 2nd and 3rd
level). Nevertheless, in those rare cases with positive
muscle biopsy proving a quantitative or qualitative dys-
trophin abnormality but without pathogenic genetic variant
identified, a clinical diagnosis of dystrophinopathy should
be concluded, since no molecular testing protocol can
currently demonstrate 100% sensitivity. This should be
taken into account as very important for Rare Disease
certification.
If a pathogenic DMD variant is not identified by analysis
for whole-exon deletions and duplications or after DMD
gene sequencing, then in some cases alternative diagnoses
should be considered, depending on the available clinical
evidence and test results. Possible alternatives, especially
for patients with milder clinical severities (for example,
those referred with suspected BMD) but also for patients
referred with DMD at an early age, might include a limb
girdle muscular dystrophy, or Emery–Dreifuss muscular
dystrophy.
For patients with additional symptoms not normally
explained by a dystrophinopathy, such as dysmorphic fea-
tures or severe learning difficulties, the possibility of a
contiguous gene syndrome should be considered when a
deletion/duplication extending to at least the first or last
exon of the DMD gene has been identified. Therefore, array
CGH testing is recommended as an additional first line test
for these patients.
For some referrals for diagnostic confirmation in patients
with a family history of dystrophinopathy, the familial
pathogenic variant may already be known. Specific testing
for the familial pathogenic variant is sufficient for these
patients. However, if the familial variant is not detected,
then further testing should be considered following the
diagnostic algorithm in Fig. 1 as, although rare, the occur-
rence of independent new pathogenic variant events in
related patients through either the paternal or maternal lines
has been reported [33].
From the patients' and relatives' perspectives, the speed
with which a diagnosis can be made is extremely important
to minimise anxiety and to reduce the risk of recurrence of
the disease in the family, as well as for variant-specific
(personalised medicine) approved treatments and enrolment
in clinical trials. Therefore, the above workflow should
always be carried out in a timely manner.
Diagnostic testing in manifesting female patients
Although the classic dystrophinopathy phenotypes of DMD
and BMD typically affect males, females can present with
DMD-, BMD-like or milder phenotypes, such as dilated
cardiomyopathy and/or mild muscle weakness [4]. As
dystrophinopathy is less well recognised in females and
symptoms may be similar to other limb girdle muscular
dystrophies, manifesting females may not receive an accu-
rate genetic diagnosis.
Most manifesting females are heterozygous for a patho-
genic DMD variant and have a milder phenotype than DMD
males. Clinical manifestation in these cases is most likely
due to skewed X-inactivation. The recommended testing
strategy in these manifesting females is equivalent to that
outlined above (and in Fig. 1) for males, i.e. CNV analysis
and sequencing if a diagnosis is strongly suspected,
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followed by muscle biopsy (enabling RNA analysis as
appropriate) if no diagnosis is made.
A small proportion of manifesting females have a DMD
phenotype and are sometimes referred to as ‘DMD-like’
girls. Additional testing is appropriate in these cases. Kar-
yotyping is recommended due to the possibility of chro-
mosomal aberrations, particularly balanced X;autosome
translocations, leading to 100% skewed X-inactivation of
the normal X-chromosome and hence the DMD phenotype
[34]. Girls with Turner syndrome (45,X) and DMD have
also been reported [35]. There are also other extremely rare
cases of DMD-like girls: cases without chromosomal
translocation but presenting with complete skewed inacti-
vation of the normal X-chromosome in skeletal muscle (38,
STG personal communication); girls with two pathogenic
variants (4, AF personal communication); girls exhibiting
uniparental disomy with a pathogenic DMD variant; or
coexistence of a pathogenic DMD variant with a pathogenic
androgen receptor variant in a phenotypically female indi-
vidual with a 46,XY karyotype [35]. Therefore, in the
absence of a chromosomal aberration, these possibilities
should be considered.
As with diagnostic testing in males, in some manifesting
females with a family history of dystrophinopathy, the
familial pathogenic variant may already be known, in which
case specific testing for the familial pathogenic variant is
usually sufficient.
Carrier testing in females
Most females referred for molecular testing are clinically
asymptomatic individuals with a family history of dystrophi-
nopathy in males. Testing is undertaken to determine whether
the individual is a carrier of dystrophinopathy, and hence this
analysis is referred to as carrier testing. However, it is important
to be aware that a significant proportion of ‘carrier’ females
develop some dystrophinopathy-related symptoms during their
lifetime (refer to ‘Reporting results’ section).
Carrier testing is important to allow adequate and
appropriate family planning, which may lead to prenatal
testing, including non-invasive prenatal diagnosis (NIPD),
or preimplantation genetic diagnosis. Individuals under-
going carrier testing should always receive appropriate
genetic counselling prior to testing.
Carrier testing for known familial pathogenic variant
When the familial pathogenic variant is known, carrier
testing should be undertaken by specific testing for this
variant. Whenever possible, a sample from the index case
(or a known carrier) should be run as a control sample or (at
least) a written laboratory report describing the variant of
the index patient should be available to avoid data
transmission problems. If the familial pathogenic variant is
a single-exon deletion or duplication, then preferably the
testing method should not rely on a single probe or primer
pair; therefore, where possible, two independent/com-
plementary tests (e.g. MLPA and Sanger sequencing, or
MLPA and microsatellite analysis, for a single-exon dele-
tion), or a single test that interrogates multiple loci within
the deletion or duplication (e.g. high density array CGH),
should be performed if there is a possibility of a false result
due to non-amplification or non-hybridisation.
If the variant in the index case cannot be found in
genomic DNA from his mother, the frequency of germline
mosaics still confers a significant recurrence risk for future
children (see ‘Reporting results’ and ‘Atypical findings’
sections below).
In exceptional cases when the DMD gene defect is
detectable only at the RNA level, the need to perform RNA
analysis from a muscle biopsy in female relatives can be
considered (or haplotype analyses performed if applicable,
see ‘Carrier testing by haplotype analysis’ section).
Carrier testing when the familial pathogenic variant is
unknown (no available proband)
When the familial pathogenic variant is unknown and an
affected male is not available to be tested, female relatives
at risk of being carriers should be offered the full cohort of
level 1 and 2 genetic testing (i.e. CNV analysis and
sequencing) since these two approaches are cost effective
and offer ~99% sensitivity.
Testing should start with the woman who has the highest
prior carrier risk. Ideally this would be an obligate carrier,
but more commonly this is the mother of an index case, and
in many cases only a more distant relative (with a lower
carrier risk) is available. Measurement of serum CK levels,
ideally in all at-risk females belonging to the pedigree, may
also be helpful in refining carrier risk prior to or alongside
genetic testing. Appropriate genetic counselling prior to
genetic testing is particularly important for these referrals
(in view of the residual risks if a pathogenic variant is not
detected).
If no pathogenic variant is detected by level 1 and 2
genetic testing, a muscle biopsy in the at-risk female
(especially for obligate carriers or females with repeatedly
high CK) might be appropriate to evaluate dystrophin
expression and for RNA studies. If not possible/available,
urine stem cell RNA studies might be helpful to identify
atypical DMD variants.
Carrier testing by haplotype analysis
Haplotype analysis, also known as linked marker analysis,
is an alternative molecular testing approach which may be
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appropriate in very rare cases, if key family members are
available and the family structure is suitable. The rare
instances when this analysis may be useful include when
there is very strong evidence of dystrophinopathy (e.g.
classic clinical signs, elevated serum CK levels and ideally
supportive muscle immunohistochemistry) and no patho-
genic variant is detected in the proband (including when a
variant of uncertain clinical significance is identified in one
or more members of the family) or when it has not been
possible to identify at the genomic level the cause of a
structural change detected at the RNA level in the proband
(refer to RNA analysis (Level 3 testing)). Carrier risk is
determined by tracing the inheritance of high and low risk
DMD haplotypes within a family. Polymorphic micro-
satellite markers and/or SNPs are used for the analysis. A
large resource of intragenic and flanking markers is main-
tained on the Leiden Muscular Dystrophy pages website
[36]. Multiple informative markers should be used, which
span the length of the gene and closely flank the gene at
each end. This is important due to the high probability of
recombination across the DMD gene. Individual haplotypes
are then constructed from these data. The results should be
interpreted and reported with care, particularly if the diag-
nosis is in any doubt (see ‘Reporting results’ section for
further information).
Prenatal diagnosis, NIPD and PGT
Considering the World Health Organization (WHO) docu-
ment on Quality & Safety in Genetic Testing [37] under the
principle of clinical utility, prenatal diagnosis for DMD/
BMD/XLDC or any dystrophinopathy phenotype that is
clinically relevant should be limited to male pregnancies
only. Indeed, at present it is not possible to predict whether
a female heterozygous for a DMD pathogenic variant will
manifest any signs of the disorder or not. Hence it is not
generally considered appropriate to offer prenatal diagnosis
for a female foetus. Nevertheless, prenatal testing of a
female foetus may be considered in some rare circum-
stances, such as documented familial recurrence of X;
autosome translocation, documented familial complete
skewed X-inactivation, or emotional and/or social motiva-
tions that are not directly linked to the DMD genotype (e.g.
the presence of a DMD-like girl in the family). The familial
pathogenic variant will preferably be known in advance of
testing a pregnancy and should be confirmed before the
prenatal test.
Prenatal diagnosis
Invasive prenatal genetic testing for dystrophinopathies is
preferentially performed on tissue (placental biopsy) from
chorionic villus sampling (CVS) in early gestation
(11–12 weeks). High DNA quality and yield is typically
obtained from CVS, allowing a wide variety of possible
testing methods (including NGS); therefore, results can be
obtained and reported rapidly (normally by 2–12 days from
sampling). Amniocentesis, typically undertaken at around
15–17 weeks gestation, may be used in rare cases, but has
the disadvantages both of being taken later in the pregnancy
and of lower DNA quality and yield from direct amniotic
fluid; therefore, amniocyte miniculture may be required (at
least 5 more days) to obtain sufficient high-quality DNA.
Testing of CVS or amniocentesis is carried out by
standard procedures. The known familial DMD gene
pathogenic variant can be tested using the appropriate
technique (CNV detection or sequencing, others for rare
atypical variants) that was previously used to identify/verify
the variant in the proband. A check for maternal cell con-
tamination (MCC) must be carried out, since its presence at
a significant level may affect the interpretation of the foetal
result. This can be achieved by the analysis of intragenic
DMD microsatellite markers that will also allow confirma-
tion of foetal sex and the result of direct mutation testing
(haplotype analysis). Alternative methods are also accep-
table. It is important to confirm foetal sex by testing the
CVS or amniocentesis material regardless of whether non-
invasive foetal sexing was previously carried out. Further
details and recommendations for checking for MCC in
prenatal samples can be found in the ACGS Best Practice
Guidelines [38].
Non-invasive foetal sexing
It is now possible to non-invasively determine foetal sex
during pregnancy, and this testing should be offered to
patients as an alternative to chorionic villus sampling or
amniocentesis as it will negate the risk of an invasive test
where the foetus is female. Non-invasive foetal sexing is
possible from 7 to 9 weeks gestation depending on local
laboratory policies, and is based on the detection of Y-
chromosome specific sequences in the maternal blood dur-
ing pregnancy [39, 40]. It is important that an ultrasound
scan be performed to accurately date and confirm a sin-
gleton pregnancy. Testing has limited benefit in twin
pregnancies, but may be helpful in the scenario where both
foetuses are demonstrated to be female as shown by com-
plete absence of Y-chromosome specific sequence. It is
important however that the test is validated on twin preg-
nancies. Testing is usually carried out using real-time PCR
for Y chromosome markers such as SRY, with a house-
keeping gene such as CCR5 as a control. There is a test
failure rate of up to 5% due to low foetal fraction, and a
very small risk of misdiagnosis due to the presence of a
vanishing twin (false positive result) or a very low foetal
fraction (false negative result).
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Non-invasive prenatal diagnosis (NIPD)
NIPD for dystrophinopathies is likely to increasingly become
feasible using methods such as relative haplotype dosage
analysis (RHDO) [41]. RHDO analysis examines SNPs in the
cell-free DNA from a maternal blood sample, and shows
whether the male foetus has inherited the high risk or low risk
haplotype across the DMD gene, in comparison to a proband
for phasing of the haplotypes. It is likely that new genomic
approaches also able to directly detect CNVs will be available
shortly due to technical and bioinformatics advances.
Prenatal diagnosis by haplotype analysis
In a few cases there may be a diagnosis of dystrophinopathy
within the family, but the pathogenic variant has not been
identified. Although both CNV detection and sequencing
can be quickly performed on the pregnant mother to identify
the pathogenic variant in the vast majority of cases, in some
rare cases, haplotype analysis using informative poly-
morphic markers is an option for prenatal diagnosis; this is
feasible only if the family structure is suitable and poly-
morphic markers are informative. Further information on
polymorphic markers is included in the carrier testing sec-
tion above. As with carrier testing, multiple informative
markers should be used, which span the entire length of the
gene. A decision should be made whether it is appropriate
to offer prenatal diagnosis by haplotype analysis prior to
prenatal sampling. The results should be interpreted with
caution, particularly if the clinical diagnosis is in any doubt
(see ‘Carrier testing’ section above and ‘Reporting results’
section for further information).
Preimplantation genetic testing (PGT)
PGT is a specialist test carried out in a limited number of
centres. For PGT, the same analytical considerations apply
as for prenatal testing, but the special requirements of a
PGT setting need to be considered. This is detailed in the
Best Practice Guidelines from the European Society of
Human Reproduction and Embryology Consortium [42].
PGT is therefore beyond the scope of these guidelines.
However, it is important to note that this type of genetic
diagnosis is appropriate and feasible for dystrophinopathies
and is applicable to both CNVs and small variants [43].
Variant annotation and interpretation
Variant annotation
Dystrophinopathies result from sequence variants in the
DMD gene (HGNC ID:2928). Although the DMD gene
encodes several transcripts/isoforms, variants are reported
in the context of NCBI RefSeq transcript NM_004006.2
which is the transcript (Dp427m) of DMD that is pre-
dominantly expressed in skeletal and cardiac muscle. The
corresponding NCBI RefSeqGene genomic DNA record is
NG_012232.1. The Locus Reference Genomic (LRG)
[44, 45] reference sequence, LRG_199, is based on these
two reference sequences with the transcript being desig-
nated t1. No other sequence records are currently supported
for the reporting of DMD gene sequence variants.
Fully characterised sequence variants should be descri-
bed in accordance with the Human Genome Variation
Society (HGVS) recommendations for description of
sequence variants [46]. This includes small sequence var-
iants (e.g. single-nucleotide substitutions and deletions,
insertions or duplications of a few nucleotides) and also
whole-exon deletions/duplications where the breakpoints
have been fully characterised at the genomic DNA level.
However, when the breakpoints of whole-exon deletions/
duplications have not been defined (e.g. when reporting
results of MLPA analyses), use of HGVS variant nomen-
clature is not required as it is complex and not readily
understandable to the referring clinician. It is important that
patient reports of whole-exon deletions/duplications include
a description that is both meaningful and understandable to
the medical community. Therefore, although HGVS variant
description recommendations do not refer to the numbering
of gene exons, as a variant should never formally be
described in the context of exon or intron numbers, it is
recommended that all whole-exon deletions/duplications be
described with reference to specific exons (e.g. deletion of
exons 2–6) in patient reports. Although exon numbering is
not controversial for DMD, it should be clear from the
report how the exons have been numbered; this is most
easily achieved by quoting LRG_199t1 as LRGs provide
exon numbering.
Interpretation of deletions and duplications
Whole-exon deletions or duplications detected in patients
with suspected dystrophinopathy can be considered patho-
genic in the vast majority of cases.
The correlation of deletions with clinical severity usually
depends on their effect on the open reading frame (a reading
frame checker is available at the Leiden Muscular Dystro-
phy pages [36]). Deletions that disrupt the translational
reading frame generally lead to complete or near-complete
absence of dystrophin protein in muscle, thereby resulting
in a severe DMD phenotype in males. In contrast, those that
preserve an open reading frame, enabling production of
either a reduced amount of normal dystrophin or an altered
but partially functional protein (with an intact C-terminus
which allows synthesis of the dystroglycan-binding region),
generally give rise to a milder BMD clinical presentation
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[47]. Application of this reading-frame rule to the coding
regions of the DMD gene thus makes it possible to predict
whether a male is likely to develop BMD or DMD [48].
While this holds true for the majority of cases, there are
several exceptions, most of which can be explained by
splicing choices (e.g. favourable exon skipping of deletion-
adjacent exons reframing the translation), lack of some
exons encoding vital protein domains (such as those
encoding the N-terminus, cysteine rich domain or C-ter-
minus) or alternative translation initiation [11, 49–52].
Indeed, even small in-frame deletions may have a severe
pathophysiological consequence; for example, those
affecting the amino-terminal actin-binding domain 1
(ABD1), encoded by exons 2–8, or the beta-dystroglycan
binding region, encoded by exons 63–70, often result in a
severe DMD phenotype [51, 53].
The detection of whole-exon duplications is accepted as
being sufficient to confirm a diagnosis in patients with
suspected dystrophinopathy. However, it is important to
note that diagnostic techniques, such as MLPA or CGH, do
not provide information about the location (tandem versus
interspersed) or orientation (head-to-tail versus inverted) of
the duplicated gene segment. Although most duplications of
one or more exons turn out to be direct tandem duplications,
in some of these presumed ‘simple’ duplications, studies at
the RNA level have revealed unexpected changes such as
partial triplications, indels and other complex rearrange-
ments [54, 55]. Additionally, some cases are confounded by
splicing choices inducing exon skipping or (partial) intronic
sequence retention. It is therefore not surprising that whole-
exon duplications have been reported to account for almost
one third of the cases behaving as exceptions to the reading
frame rule [1]. The possibility of duplications involving
extragenic regions (on the X chromosome or on autosomes)
due to unequal crossing over and non-homologous end
joining is also an issue, as recently reported [56]. Most
extreme of all, it is possible, although highly unlikely in an
individual with suspected dystrophinopathy, that an appar-
ent duplication could be inserted elsewhere in the genome
and hence not disrupt the DMD gene. For all these reasons,
the reading frame rule should be applied with caution for
duplications.
Interpretation of small sequence variants
Sequencing of genomic DNA or cDNA may identify small
sequence variants in the DMD gene. The majority of
pathogenic DMD small variants are nonsense, frameshift or
splicing variants, while missense variants are rare (Table 1).
For any small variant identified within the DMD gene,
evidence for pathogenicity must be assessed. The inter-
pretation of variant pathogenicity should be undertaken in
accordance with international guidelines on sequence
variant interpretation, currently the ACMG/AMP consensus
recommendations [57]. Therefore, the variant investigation
process is not described in detail here, but important con-
siderations include: concordance with the clinical, bio-
chemical and histological phenotype; presence/frequency in
population-based cohorts (e.g. the Genome Aggregation
Database [58]); previous reports in association with dys-
trophinopathy, including checking the DMD locus specific
databases (Leiden Open Variation Database, LOVD [3],
which includes information on whether a given variant has
been associated with DMD, BMD and/or other phenotypes;
UMD-DMD France database [59]) and ClinVar [60]; any
RNA or protein functional studies in the literature or for the
specific patient; in silico predictions including conservation
across species, predicted consequence of amino acid sub-
stitutions (for missense variants) and splicing algorithms.
Frameshift variants
Frameshift variants typically lead to the generation of
multiple premature stop codons, leading to (variably)
reduced levels of full length transcripts and translational
failure, therefore, being causative of a dystrophinopathy,
mostly a DMD phenotype.
Nonsense variants
Nonsense variants are single nucleotide substitutions lead-
ing to a nonsense codon instead of an amino acid-specific
codon; again, they are generally pathogenic as a result of
(variably) reduced levels of full length transcripts and
translational failure, mostly leading to a DMD phenotype.
However, a number of exceptions are on record of in-
frame exon skipping associated with some frameshifting or
nonsense variants (also rare cases of missense or even
synonymous variants) weakening the splicing recognition
sequences (i.e. exon splicing enhancers or ESEs), thereby
changing the severity of the phenotype [50, 61]. Also, at the
extreme 3′ end of the gene, nonsense variants may lead to a
milder phenotype than expected for reasons not completely
understood [62, 63]. At the extreme 5′ end of the gene,
alternative translation initiation beginning in DMD exon 6
can reduce the expected severity of DMD nonsense variants
lying within the first few exons of the gene [52, 64].
Splicing variants
Genomic variants located in the canonical splice sites,
acceptor (positions –1 and –2) and donor (positions +1 and
+2), will almost invariably lead to aberrant splicing as they
affect strongly conserved dinucleotides that define
exon–intron boundaries. Bioinformatics in silico tools can
be used to support the prediction that the splice site is
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abolished (the splice site is generally no longer recognised
or its score is drastically reduced). Variants may also occur
in less conserved regions of the splicing consensus
sequences (e.g. the final two nucleotides of exons, splice
donor site positions +3 to +6, splice acceptor poly-
pyrimidine tract and the branchpoint). In silico predictions
for these variants are less precise. It is recommended to use
multiple software programs (at least three) to give a con-
sensus prediction. There is no consensus on the threshold
cut-off value and this should be adapted (usually from 5 to
15%) depending on the prediction tool [65, 66]. These tools
are also able to predict newly created cryptic splice sites. In
all cases, these are only predictions. A splice site variant can
have different effects on transcripts (single or double exon
skipping, use of de novo splice sites, activation of a cryptic
splice site and pseudo-exon inclusion, retention of introns or
even a combination of these). Therefore, if possible, muscle
RNA analysis should be performed or recommended for
reading frame determination and clinical interpretation,
which can be supported in this case by the immunohisto-
chemical analysis of dystrophin.
Apart from the loss or the gain of a splice site, deter-
mining whether other exonic or intronic DNA variants can
lead to aberrant splicing is more complex. In theory any
intronic or exonic (nonsense, missense, synonymous)
sequence variation might affect splicing by changing
(creation or disruption) splicing regulatory elements.
However, in view of the current absence of reliable bioin-
formatics programs to predict these cis-acting elements,
muscle RNA analysis in the patient or functional assays are
required for the classification of such variants. The above-
mentioned exon skipping-associated nonsense variants and
the reported case of a pseudo-exon activation [67] are
examples of such mechanisms.
Missense variants
Pathogenic missense variants in the DMD gene are rare and
can cause DMD, BMD or X-linked cardiomyopathy. Var-
iants leading to amino acid substitutions should be checked
for their predicted effect on protein structure and function
by suitable algorithms, such as SIFT [68] and PolyPhen-2
[69]. With a huge, still not fully characterised, protein like
dystrophin, the limited power of such predictions should be
recognised. A significant proportion of reported missense
variants are located in the ABD1 of dystrophin for which
the crystal structure has been determined [70]; these fre-
quently lead to a BMD phenotype. Another subset of mis-
sense variants lie in the ZZ domain of the C-terminal region
of the protein; these variants are typically reported in
patients with a severe Duchenne phenotype in spite of
showing persistence of dystrophin staining in muscle in
some cases [71]. The interpretation of previously
unreported missense variants or variants located in other
protein domains is more complicated and currently relies
only on in silico analyses. The possibility of splicing
effects, as discussed above, should also be considered.
Reporting results
Introduction/general comments
Reporting genome/gene variants is the crucial final step of
genetic diagnosis, and the report represents a lifelong dur-
able document for the patient and his/her relatives, that
rarely needs to be revised or updated. The report should be
comprehensible on its own, written in clear (though spe-
cific) language and provide a fully interpretative and
authoritative answer to the clinical question, thus containing
all necessary information for the reader.
General guidelines on reporting results of diagnostic
genetic testing, including guidance on report format and
essential information, have previously been published to aid
harmonisation of European reporting practice [72]. There-
fore, these guidelines should be adhered to and further
general information is not provided here.
When reporting genetic testing of the DMD gene, an
appropriate reference sequence accession number (including
version where applicable) must be included (refer to variant
annotation section above). The analysed gene regions
(exons, full coding sequence, etc.) and methods used
(referring to commercial kit reference and version numbers
if applicable) should be specified. If an NGS method is
used, any exons/regions not covered should be outlined and
the alternative/additional methods used (e.g. Sanger
sequencing) to sequence the uncovered exons should be
indicated.
HGVS variant nomenclature is the gold standard for
variant annotation on reports (refer to variant annotation
section above). However, for deletions or duplications of
one or more exons of the DMD gene, a description with
respect to exons (e.g. deletion of exons 2–6) is more easily
understandable to the report reader, and is, therefore,
recommended. HGVS nomenclature must be used for small
sequence variants and may optionally be included for CNVs
(along with the description with respect to exons).
Diagnostic reports
Variant detected
When reporting a variant, it is recommended to describe the
variant type (deletion, duplication, frameshifting, nonsense,
missense, splicing, other complex variants) to impart clarity
to the report. The zygosity should also be stated, i.e.
hemizygous or heterozygous. It is essential to report the
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pathogenicity of the variant, i.e. pathogenic, likely patho-
genic or uncertain significance. Variants classified as benign
or likely benign are not routinely included in patient reports.
Rare and inherited disease genomic reporting practice for
variants of uncertain significance is controversial and varies
between centres [73]. Therefore, review of this topic for
wider genetics and genomics reporting is beyond the scope
of these guidelines. However, for diagnostic tests for dys-
trophinopathy, where no pathogenic or likely pathogenic
variant is detected, variants of uncertain significance should
generally be reported, as it may be possible to further
investigate pathogenicity in a number of ways, including
muscle immunocytochemistry, muscle RNA analysis and
segregation studies.
For deletions of one or more exons, the predicted effect
on the reading frame should also be stated, underlining that
it is a prediction without diagnostic value. This may
optionally be stated for duplications, although with greater
caution for reasons discussed previously. If the DMD
mRNA profile has been characterised, the effect on the
mRNA should be reported including the impact on the
reading frame.
For a pathogenic or likely pathogenic variant, state that
the result confirms, or is consistent with, the diagnosis of
dystrophinopathy. If the patient’s phenotype is consistent
with the predicted severity of the variant, then the report can
specifically state that the result confirms, or is consistent
with, either DMD or BMD. If the phenotype does not
appear consistent with the predicted severity of the variant,
the diagnosis of dystrophinopathy is still confirmed, but the
report may optionally comment that further analysis could
be undertaken (e.g. muscle RNA analysis).
When reporting a variant of uncertain significance, the
report should state that the result neither confirms nor
excludes a diagnosis of dystrophinopathy. The possibility of
further investigations (such as testing other family members
and/or muscle biopsy for immunocytochemistry and RNA
analysis) should also be included in the report.
Reports should also suggest referral for genetic
counselling.
The same considerations apply to reporting results of
diagnostic testing in manifesting females as for males,
although in the absence of information on skewed X-
inactivation or RNA analysis, it is not possible to comment
on the genotype/phenotype correlation and genetic prognosis.
No variant detected
The report should state that the result neither confirms nor
excludes a diagnosis of dystrophinopathy (or convey this
meaning using alternative phrasing). The sensitivity of the
test(s) must be given. Guidance on test sensitivity is
included in the ‘Carrier test reports’ section below; this will
be very high (~99%) following level 2 testing and higher
still after level 3 testing. Depending on which stage of the
diagnostic algorithm (Fig. 1) the report is being issued, the
possibility of further testing should be commented on. This
applies equally for males and females.
Carrier test reports
Variant detected
State that the variant is heterozygous (assuming this is
the case).
For a pathogenic variant, state that the individual is a
carrier of dystrophinopathy/DMD/BMD (as appropriate).
For females proven to be carriers, the report should also
state that the individual is at risk of clinical symptoms,
particularly cardiomyopathy, given the known risk for car-
riers to develop age-dependent cardiomyopathy [74, 75] and
also skeletal muscle weakness [75]. It may also be helpful to
recommend clinical follow up with cardiac function
surveillance.
The feasibility of prenatal diagnosis, including PGT,
should be mentioned. Carrier testing and genetic counsel-
ling may also be offered to other appropriate relatives.
No variant detected
When the familial pathogenic variant is not present in a
carrier test, state that the individual is not a carrier of the
familial variant. However, an exception to this is when
testing the mother of an affected individual(s) with no
previous family history of dystrophinopathy (sporadic
cases); in this case, state that the mother may be a germline
mosaic and include an estimate of the consequent recur-
rence risk for offspring; up to date published data should be
used to estimate this risk, currently Helderman-van den
Enden et al. [5] (also refer to Mosaicism in the ‘Atypical
findings’ section below); depending on local practice, pre-
natal diagnosis may be offered.
When the familial pathogenic variant is not known and
no variant is detected, the carrier risk will be reduced. The
report should state the prior and posterior carrier risks as
well as the test sensitivity. The posterior risk should be
calculated using Bayesian methods; detailed worked
examples are included in Bridge [76] and Young [77].
Laboratories should determine test sensitivity for the tests/
methods used. The following estimates of sensitivity may
be appropriate and are provided for guidance, based on the
European data summarised in Table 1:
● Sensitivity of analysis for deletions/duplications of one
or more exons for dystrophinopathy (phenotype
unknown)—78%
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● Sensitivity of analysis for deletions/duplications of one
or more exons for DMD—75%
● Sensitivity of analysis for deletions/duplications of one
or more exons for BMD—88%
● Sensitivity of analysis for deletions/duplications of one
or more exons AND sequencing of the coding region
and exon/intron boundaries for dystrophinopathy (all
phenotypes)—99%
Laboratories may prefer to use their own data/figures.
Overall sensitivity may vary slightly between populations
and is also dependent on the analytical sensitivity of the
testing method(s) used.
Haplotype analysis
As discussed in the genetic testing strategy section, haplo-
type analysis may be undertaken to assess carrier status in
rare cases where the familial pathogenic variant has not
been identified (including when a variant of uncertain sig-
nificance has been identified). Individual haplotypes should
be constructed from the observed alleles and displayed in a
pedigree drawing. Carrier risks should be calculated based
on the segregation of high- and low-risk haplotypes, using
Bayesian methods as described in worked examples pub-
lished by Bridge [76] and Young [77]. In cases where a
recombination is observed, calculations become more
complex and may need to consider the relative likelihood of
the unidentified pathogenic variant residing on either side of
the recombination. A report or genetic counselling docu-
ment for multiple family members is required to summarise
the results, as a single individual genetic report will not be
meaningful. This document should estimate the prior and
posterior carrier risks, including all available pedigree
information and any data on serum CK levels in women at-
risk of being carriers. As stated previously, considerable
caution should be exercised when reporting results of hap-
lotype analysis; the report document should clearly state
that the interpretation assumes the diagnosis of dystrophi-
nopathy in the family is correct (i.e. that the disorder is due
to a defect in the DMD gene).
Prenatal diagnosis
When the familial variant is detected in a male pregnancy,
reports should state that the foetus is predicted to be affected
with DMD, BMD or dystrophinopathy (as appropriate). In
the case of prenatal diagnosis for possible germline
mosaicism risk, i.e. for a male pregnancy in a mother who
has previously had a child with dystrophinopathy but is not
herself a somatic carrier of the pathogenic variant, detection
of the familial variant in the male foetus demonstrates that
the mother is a germline mosaic. This should be
documented in the report, additionally stating that the
recurrence risk in future pregnancies is increased relative to
the risk prior to this result but remains less than the risk of
transmission (50%) from a carrier mother.
When the familial variant is not detected in a male
pregnancy, it should be stated that the foetus is predicted
not to be affected with DMD, BMD or dystrophinopathy (as
appropriate).
Reports should state which variant(s) was/were tested
for, and that maternal cell contamination was excluded.
Where prenatal diagnosis is performed by NIPD using
RHDO analysis, it is important to also include test-specific
performance information such as the risk of a false-positive
or false-negative result.
Rare cases of invasive prenatal diagnosis by haplotype
analysis should be interpreted and reported as summarised
above for carrier testing by haplotype analysis.
Atypical findings
Although simple CNVs and small variants in exons or
flanking intronic sequences account for roughly 98% of
pathogenic variants associated with dystrophinopathy,
many types of atypical pathogenic variants do occur.
Non-contiguous exon deletions or duplications
This is not an infrequent finding and may be identifiable by
standard quantitative tests for CNVs (such as MLPA).
Deletion or duplication of non-contiguous exons should
always be further analysed. Following exclusion of allele
drop-out due to SNPs within primer-binding sites, whole-
genome CGH and/or RNA studies are helpful to define the
DMD locus architecture and/or the RNA profile. These
studies are required to confirm the pathogenic effect that the
rearrangement may have on the reading frame.
Dual DMD variants
In rare males (in cis) or in females (in cis or trans) two
pathogenic DMD variants can be found [78]. In these cases,
family segregation analysis is mandatory: in males to define
their occurrence (inherited or de novo) and pathogenicity; in
females to define the parental origin and the resulting
genotype. RNA studies may also be helpful to define their
pathogenicity.
Variants in DMD alternative first exons or UTRs
CNV detection or sequencing procedures routinely analyse
the muscle first exon only (first exon used for dystrophin
muscle isoform or Dp427m). However, six other alter-
natively used first exons are represented in the dystrophin
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isoforms Dp427c, Dp427p, Dp260, Dp140, Dp116 and
Dp71. Although not routinely analysed, other than CNV
analysis of Dp427c by MLPA, pathogenic variants in the
six alternative first exons have never been reported. In
addition, given the prominent muscle (skeletal and cardiac)
phenotype in dystrophinopathies, it is important to note that
the only isoform other than Dp427m that is well expressed
in striated muscle is the Dp427c [79, 80].
The entire untranslated regions (UTRs) at the 5′ or 3′
ends of the DMD gene are not completely explored in
routine diagnostic testing. Pathogenic variants in these
UTRs may occur, although very rarely. The first 200 bp of
the 3′ UTR are routinely analysed by CNV analysis and
sequenced in some laboratories, and indeed pathogenic
variants have been reported [3].
Contiguous gene syndromes
Contiguous gene syndromes that include the DMD gene are
extremely rare, for example complex glycerol kinase defi-
ciency [81]. When atypical or ‘plus’ phenotypes occur,
karyotype and high-density whole-genome CGH are
recommended to identify complex rearrangements and
related gene/genomic breakpoints possibly involving extra-
DMD regions and further genes. Accurate identification of
these cases is extremely important to address appropriate
care and therapy, for genetic counselling in the family, and
for trial enrolment.
Mosaicism
Pathogenic DMD variants can be present in the mosaic
state, both somatic and germline.
Germline mosaicism in apparently non-carrier mothers of
sporadic cases of dystrophinopathy is well described, and
the recurrence risk for the at-risk haplotype has been esti-
mated to be ~9% (although this can be refined based on
variant type) [5]. Appropriate reporting of this possibility
has been discussed above.
Somatic mosaicism has only been described in a few rare
cases, mostly in females. Identifying these individuals is,
however, extremely important for carrier identification and
prenatal testing. There are some reported cases, where
somatic mosaic female carriers escaped detection on ana-
lysis of blood DNA, and therefore missed accurate carrier
diagnosis and prevention [82].
Males with mosaicism for DMD variants have also been
reported, though very rarely [83, 84]. They generally pre-
sent with milder symptoms of the disease, and in some
cases there is genetic normalisation in muscle over time. It
can be difficult to identify these male patients by routine
diagnosis, because the mild clinical symptoms often differ
from classical dystrophinopathy phenotypes. The high
diagnostic sensitivity of NGS methods (when a high
sequence-read depth approach is adopted) facilitates the
detection of DMD mosaicism, providing more insights
about these rare phenotypes and the levels of mosaicism in
different tissues [85].
Personalised medicine, therapies and clinical trials
In the last 10 years, dystrophinopathies’ stakeholders
experienced a flowering of novel drugs and clinical trials
[86]. These new therapeutic options greatly accelerated
research into the pathophysiology of dystrophinopathies
and also positively impacted on the standard of care and
genetic diagnosis. Indeed, both accurate clinical outcome
measures and accurate genetic profile are compulsory for
clinical trial design. To date, this intense activity has only
involved Duchenne muscular dystrophy, with the main
therapeutic options being as follows: (i) reframing the DMD
transcript via exon skipping which is induced by a synthetic
antisense oligoribonucleotide (eteplirsen, golodirsen, casi-
mersen and drisapersen) omitting exon 51, 53, 45 or 44
respectively; (ii) ribosomal read-through of nonsense var-
iants (ataluren), which is based on the known low specifi-
city of tRNAs in cognate codon recognition; (iii) gene
therapy based on minigenes which encode shortened forms
of dystrophin. These new trials and treatments strongly
impact on genetic testing, since the genetic result is needed
to make patients eligible and enrollable in these trials.
Information on drug eligibility is beyond the obligations
of a diagnostic genetic report for dystrophinopathy and
currently it is preferable not to include this in the report.
However, mention of relevant information is acceptable
where this is in accordance with local policy and current
practice.
Incidental findings
Increasingly, genome-wide testing is being undertaken for
many different clinical indications, and this may identify
variants in the DMD gene in patients where a clinical
diagnosis of dystrophinopathy has not been considered or
suspected. This includes whole-genome sequencing, whole-
exome sequencing, gene panel analysis and array CGH. In
particular, the wide use of array CGH in many centres is
identifying cases of deletions or duplications of one or more
exons of the DMD gene (e.g. ~1 in 500 array CGH tests in
one centre, CF personal communication), often in children
with developmental delay or learning difficulties, but also
for a range of other scenarios including prenatal array CGH
testing.
These ‘incidental’ findings of hemizygous (males) or
heterozygous (females) DMD variants must be interpreted
with caution.
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CNVs of potential clinical significance identified by
array CGH are reported as part of routine practice. Pub-
lished guidelines on reporting of incidental findings from
NGS panels, exome or genome sequencing should be
referred to when considering reporting DMD variants
identified by these methods [87].
Male patients
In a male patient in whom there has been no clinical sus-
picion of dystrophinopathy, the prior probability of a DMD
variant being pathogenic is lower than in a patient referred
with classical symptoms of dystrophinopathy and highly
elevated serum CK levels. Similarly, the prior probability
that a pathogenic DMD variant is associated with high
penetrance and expressivity is also lower.
Although deletions of one or more exons of the DMD
gene are almost always pathogenic, several cases with
minimal phenotypic expressivity have been reported;
examples include asymptomatic males aged over 60 years
with deletions of exons 48–51, 48–53 and 45–51 [88, 89] or
a single exon 48 deletion [90]. Therefore, when reporting
deletions identified as ‘incidental’ findings, it is recom-
mended to state that their penetrance and expressivity is
uncertain.
For duplications of one or more exons, in addition to the
uncertainty regarding penetrance and expressivity, the
location and orientation of the duplication is normally
unknown (e.g. if detected by array CGH). Therefore,
although any duplication is most likely to be a direct tandem
duplication within the DMD gene, without additional ana-
lysis this is not certain; the duplicated region could, for
example, be on an autosome and hence not disrupt the DMD
gene (e.g. case of DMD exons 45–51 duplication located on
chromosome 17; CF personal communication). Therefore,
when a duplication is detected as an ‘incidental’ finding,
this cannot demonstrate a diagnosis of dystrophinopathy
and further investigations are indicated (see below).
Small DMD gene variants should be interpreted with
similar caution to exonic deletions. Therefore, it is recom-
mended to state that their penetrance and expressivity is
uncertain.
In all cases, further investigations are recommended. The
simplest follow-up to further investigate a possible diag-
nosis of dystrophinopathy is normally to recommend clin-
ical and biochemical (serum CK measurement) assessment.
Some centres/laboratories may be able to obtain this infor-
mation prior to issuing a report, and this can be extremely
helpful. If the clinical and biochemical investigations are
strongly suggestive of a dystrophinopathy, then the results
can then be reported in the same way as for routine diag-
nostic referrals. Conversely, if clinical and biochemical
assessment does not support a dystrophinopathy, then it
may be possible to dismiss the variant as not associated with
disease; however, caution should be exercised due to the
possibility of variable penetrance and expressivity within a
family [91]. When the clinical significance of a variant
remains uncertain, family studies may be helpful, typically
beginning with testing the patient’s mother (and father for
duplications where the location of the duplication is
unknown) to determine whether the variant has arisen
de novo. Testing other at-risk male relatives, following
clinical and biochemical assessment, can also be informa-
tive if they are found to have the variant. Of course, any
family studies should be supported by appropriate genetic
counselling. Finally, for duplications, further molecular
testing to determine the location and orientation may be
possible, for example by long-range PCR, FISH or RNA
analysis.
In cases where the DMD variant is pathogenic and
clinical assessment supports a diagnosis of dystrophino-
pathy, this may explain the patient’s symptoms if they are
known to be associated with dystrophinopathy. For exam-
ple, for a male patient referred with developmental delay,
this may be a gross motor delay entirely consistent with a
classic dystrophinopathy phenotype. Also, for a male
patient with learning difficulties, the DMD gene variant may
be responsible as intellectual disability or cognitive
impairment has been reported in a proportion of males with
dystrophinopathy, particularly when the pathogenic variant
is towards the 3′ end of the gene (exon 45 or beyond; likely
due to impact on short dystrophin isoforms expressed in the
brain) [92, 93].
Female patients
For females in whom there has been no clinical suspicion of
dystrophinopathy, again the prior probability of a DMD
variant being pathogenic is much lower than in a patient
referred with symptoms suggestive of dystrophinopathy.
However, the situation is further complicated by the fact
that DMD/BMD carriers are likely to be asymptomatic and
so there are unlikely to be any clinical symptoms to cor-
relate with the DMD genotype.
In general, the same cautionary notes regarding patho-
genicity, penetrance and expressivity of deletions, duplica-
tion and small variants in the DMD gene apply as
summarised for ‘incidental’ findings in males above.
Therefore, even for variants that are normally expected to
be pathogenic (such as deletions of one or more exons), it is
recommended to state that the penetrance and expressivity
is unknown.
Further investigations are recommended for females in
whom a heterozygous DMD variant is identified as an
‘incidental’ finding. Clinical and biochemical (serum CK
measurement) assessment may be helpful, but, unless this is
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suggestive of a manifesting female, these investigations are
unlikely to determine whether the variant will be associated
with a dystrophinopathy phenotype in males. Therefore,
parental testing is recommended whenever possible to
determine the inheritance pattern. In rare cases, the variant
will have been inherited from the proband’s asymptomatic
father; for example, Nguyen et al. [94] reported two such
families, one with deletion of DMD exon 48 and the other
with deletion of exons 3–9, indicating that these deletions
have low penetrance and expressivity in these two families.
Referral to a Clinical Geneticist and/or Genetic Counsellor
is also recommended. If the variant has been inherited from
one of the parents, the geneticist/counsellor will be able to
take a detailed family history to review whether this is
suggestive of a dystrophinopathy in the family. Testing
other at-risk male relatives may then be informative, as
discussed above for male patients. Again, for duplications,
further molecular testing to determine the location and
orientation may be possible.
Prenatal samples
DMD deletions or duplications may also be detected as
incidental findings in foetal samples during pregnancy by
prenatal array CGH testing. As described above, deletions
may be associated with reduced penetrance and/or expres-
sivity, and there may be further uncertainty for duplications.
Therefore, segregation/family studies are always needed to
define pathogenicity in the family. In some cases, the
clinical significance and/or pathogenicity of the DMD var-
iant may remain uncertain.
Historical results
In known dystrophinopathy families, previous genetic
testing at the DMD locus may date as far back as the mid-
1980s. Results of these historical tests are often difficult to
interpret and/or understand, are unlikely to be as definitive
as current testing, and in many cases were carried out in
research laboratories or other non-accredited laboratories.
Therefore, when a new referral arises in such a family and
when no recent genetic testing has been undertaken, it is
recommended that genetic testing be repeated using current
techniques.
Discussion
These guidelines constitute an update of previous European
guidelines [7] and describe best practice for diagnostic and
family genetic testing and reporting for dystrophinopathies.
Updated guidelines were required, due to the application of
new genetic technologies in diagnostics and the availability
of new personalised drugs since 2010.
Draft updated recommendations prepared by the authors
were disseminated to a global network of molecular
geneticists and clinicians (from 135 laboratories who have
participated in the EMQN external quality assessment
scheme for DMD and UK diagnostic laboratories) for
consultation and amendments. Approximately 20 comments
were received and appraised by the authors; all were minor
and the guidelines were modified to incorporate the majority
of the suggestions.
Key updates and additions since the 2010 guidelines
include: use of NGS in diagnostics; non-invasive prenatal
diagnosis; guidance on sequence variant annotation and
interpretation; atypical findings; implications for persona-
lised medicine and clinical trials; and identification of DMD
gene variants in patients where a clinical diagnosis of
dystrophinopathy has not been suspected (incidental
findings).
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